Skip to main content
OpenTrials
Completed

NCT Number: NCT00034983

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)

A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

About this study

The duration of treatment is 1 year.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Major Depressive Disorder

Treatment and study plan

Aprepitant

Drug

Other names: MK0869

Comparator: paroxetine HCL

Drug

Primary outcomes

  1. Long-term safety and tolerability.

    Time frame: Duration of treatment

Secondary outcomes

  1. Sexual dysfunction adverse experiences and gastrointestinal disturbance adverse experiences

    Time frame: Duration of treatment

Sponsors and collaborators

Lead sponsor

Merck Sharp & Dohme LLC

Industry

Registry information

Official study title

A Worldwide, Multicenter, Double-Blind, Parallel, Active-Controlled, Long-Term Safety Study of MK0869 in Outpatients With Major Depressive Disorder

Important dates

Study start
2001
Primary completion
2003
Study completion
2003
First posted
May 3, 2002
Registry last updated
Apr 26, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.